EDP 305

Drug Profile

EDP 305

Alternative Names: EDP305

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Primary biliary cirrhosis

Most Recent Events

  • 20 Nov 2017 EDP 305 receives Fast Track designation for Primary biliary cirrhosis in USA
  • 23 Oct 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Non-alcoholic fatty liver disease released by Enanta Pharmaceuticals
  • 23 Oct 2017 Enanta Pharmaceuticals intends to initiate a phase II trial in Primary biliary cholangitis by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top